Acurx Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

12 Months Ended

Dec. 31, 2024

NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of December 31, 2024 and 2023 were as follows:


	December 31, 2024		December 31, 2023
Accrued research and development	$	2,664,065	$	2,263,934
Accrued compensation expenses		537,630		716,307
Accrued professional fees		36,360		58,388
Other accounts payable and accrued expenses		4,787		3,809
Total	$	3,242,842	$	3,042,438